Security
Amylyx Pharmaceuticals, Inc. Common Stock · AMLX
AMLXNASDAQCommon stockCurrentCIK 1658551Updated Oct 8, 2026
AMLX price & chart
Loading TradingView…
NASDAQ:AMLX on TradingView ↗About the company
At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.
In the news
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS News provided by Halper Sadeh LLP Jan 29, 2026, 17:05 ET Share this article Share to X Share this article Share to X Shareholders should contact the firm immediately as there may be limi ↗
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS News provided by Halper Sadeh LLP Nov 28, 2025, 18:40 ET Share this article Share to X Share this article Share to X Shareholders should contact the firm immediately as there may be limi ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 362,741,000Source | 250,713,000Source | 264,564,000Source | 194,598,000Source | 332,162,000Source | 293,603,000Source | 219,676,000Source | 417,457,000Source | 332,645,000Source | 193,634,000Source | 517,454,000Source | 391,453,000Source |
| Property, Plant and Equipment, NetUSD | 399,000Source | 1,252,000Source | 199,000Source | 445,000Source | 1,473,000Source | 212,000Source | 816,000Source | 2,459,000Source | 310,000Source | 961,000Source | 2,686,000Source | 2,611,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 225,178,000Source | 71,839,000Source | 49,326,000Source | 58,085,000Source | 74,999,000Source | 229,136,000Source | 59,764,000Source | 170,552,000Source | 226,651,000Source | 77,391,000Source | 170,201,000Source | 62,526,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 132,000Source | 1,731,000Source | — | 103,000Source | 4,091,000Source | — | 300,000Source | 20,351,000Source | 88,000Source | 447,000Source | 40,050,000Source | 15,306,000Source |
| Inventory, NetUSD | — | — | — | — | — | — | — | — | — | — | 38,323,000Source | 9,769,000Source |
| Assets, CurrentUSD | 353,383,000Source | 245,263,000Source | 256,338,000Source | 186,890,000Source | 326,722,000Source | 285,024,000Source | 216,144,000Source | 410,534,000Source | 323,671,000Source | 189,432,000Source | 464,666,000Source | 382,133,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,261,000Source | 9,137,000Source | 5,578,000Source | 5,961,000Source | 12,819,000Source | 5,256,000Source | 11,776,000Source | 16,890,000Source | 6,604,000Source | 12,484,000Source | 14,931,000Source | 10,113,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,476,000Source | 5,100,000Source | 4,541,000Source | 5,812,000Source | 2,769,000Source | 4,881,000Source | 1,256,000Source | 3,252,000Source | 5,181,000Source | 1,771,000Source | 3,725,000Source | 5,524,000Source |
| Other Assets, NoncurrentUSD | 2,500,000Source | 482,000Source | — | — | 479,000Source | 2,500,000Source | 11,000Source | 493,000Source | — | 24,000Source | 701,000Source | 466,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 30,745,000Source | 54,510,000Source | 25,397,000Source | 26,721,000Source | 70,853,000Source | 20,442,000Source | 18,259,000Source | 93,021,000Source | 27,386,000Source | 28,869,000Source | 84,022,000Source | 50,846,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 11,000Source | 7,000Source | 11,000Source | 9,000Source | 7,000Source | 11,000Source | 9,000Source | 7,000Source | 11,000Source | 7,000Source | 7,000Source | 7,000Source |
| Retained Earnings (Accumulated Deficit)USD | -718,428,000Source | -569,146,000Source | -836,134,000Source | -684,042,000Source | -496,442,000Source | -792,711,000Source | -642,599,000Source | -423,742,000Source | -751,427,000Source | -606,692,000Source | -304,949,000Source | -354,220,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 815,000Source | 641,000Source | 19,000Source | 551,000Source | -97,000Source | 240,000Source | 0Source | -77,000Source | 404,000Source | -92,000Source | 197,000Source | -86,000Source |
| Stockholders' Equity Attributable to ParentUSD | 331,996,000Source | 196,203,000Source | 239,167,000Source | 167,877,000Source | 261,309,000Source | 273,161,000Source | 201,417,000Source | 324,436,000Source | 305,259,000Source | 164,765,000Source | 433,432,000Source | 340,607,000Source |
| Additional Paid in Capital, Common StockUSD | 1,049,598,000Source | 764,701,000Source | 1,075,271,000Source | 851,359,000Source | 757,841,000Source | 1,065,621,000Source | 844,007,000Source | 748,248,000Source | 1,056,271,000Source | 771,542,000Source | 738,177,000Source | 694,906,000Source |
| Liabilities and EquityUSD | 362,741,000Source | 250,713,000Source | 264,564,000Source | 194,598,000Source | 332,162,000Source | 293,603,000Source | 219,676,000Source | 417,457,000Source | 332,645,000Source | 193,634,000Source | 517,454,000Source | 391,453,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 25,791,000Source | 53,915,000Source | 21,150,000Source | 21,424,000Source | 70,081,000Source | 15,966,000Source | 17,932,000Source | 91,639,000Source | 22,688,000Source | 28,406,000Source | 82,042,000Source | 46,609,000Source |
| Operating Lease, Liability, CurrentUSD | 981,000Source | 1,972,000Source | 1,008,000Source | 665,000Source | 2,369,000Source | 1,155,000Source | 1,055,000Source | 2,312,000Source | 1,259,000Source | 1,518,000Source | 2,257,000Source | 2,040,000Source |
| Accounts Payable, CurrentUSD | 5,339,000Source | 1,487,000Source | 5,533,000Source | 3,294,000Source | 4,955,000Source | 3,529,000Source | 4,810,000Source | 21,453,000Source | 3,519,000Source | 2,939,000Source | 22,061,000Source | 6,257,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,954,000Source | 595,000Source | 4,247,000Source | 5,297,000Source | 772,000Source | 4,476,000Source | 327,000Source | 1,382,000Source | 4,698,000Source | 463,000Source | 1,980,000Source | 4,237,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 19,471,000Source | 50,456,000Source | 14,609,000Source | 17,465,000Source | 62,757,000Source | 11,282,000Source | 12,067,000Source | 67,874,000Source | 17,910,000Source | 23,949,000Source | 57,724,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,429,000Source | 607,000Source | 1,328,000Source | 1,379,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Short-term InvestmentsUSD | — | — | — | — | 234,813,000Source | — | — | 202,741,000Source | — | — | 201,161,000Source | 284,419,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -41,284,000Source | -35,907,000Source | -144,735,000Source | -301,743,000Source | 49,271,000Source | -198,375,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 6,120,000Source | 6,833,000Source | 27,645,000Source | 33,038,000Source | 37,161,000Source | 21,714,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | -147,000Source | -359,000Source | -39,602,000Source | 24,744,000Source | 15,306,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | 0Source | — | 9,253,000Source | 73,129,000Source | 9,769,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 10,000Source | 1,871,000Source | 580,000Source | -19,102,000Source | 15,882,000Source | 1,854,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -36,882,000Source | -39,824,000Source | -123,343,000Source | -167,647,000Source | 11,919,000Source | -179,871,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 36,262,000Source | -43,659,000Source | 14,039,000Source | 75,654,000Source | 92,053,000Source | -238,988,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 11,000Source | 138,000Source | 157,000Source | 1,241,000Source | 2,526,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,217,000Source | 65,662,000Source | 257,029,000Source | 348,000Source | 3,543,000Source | 431,789,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 2,486,000Source | -17,624,000Source | 148,799,000Source | -92,083,000Source | 107,675,000Source | 12,865,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 226,161,000Source | 73,280,000Source | 50,312,000Source | 59,536,000Source | 230,122,000Source | 61,213,000Source | 227,636,000Source | 78,837,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | -30,000Source | -1,038,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -111,000Source | 197,000Source | 1,074,000Source | -438,000Source | 160,000Source | -65,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 7,076,000Source | 6,803,000Source | 8,318,000Source | 7,350,000Source | 6,120,000Source | 6,833,000Source | 27,645,000Source | 33,038,000Source | 37,161,000Source | 21,714,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | 0Source | 0Source | — | — | — | — | 0Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | — | 98,000Source | 156,000Source | 525,000Source | 904,000Source | 1,088,000Source | 487,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 46,000Source | -393,000Source | 5,026,000Source | 774,000Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | 92,500,000Source | 3,300,000Source | — |
| Investment Income, InterestUSD | — | — | 1,821,000Source | 3,098,000Source | 2,323,000Source | 1,960,000Source | 2,570,000Source | 2,231,000Source | 9,302,000Source | 13,809,000Source | 16,155,000Source | 4,291,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,386,000Source | -72,704,000Source | -43,423,000Source | -41,443,000Source | -41,284,000Source | -35,907,000Source | -144,735,000Source | -301,743,000Source | 49,271,000Source | -198,375,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,641,000Source | 2,957,000Source | 2,270,000Source | 1,414,000Source | 2,495,000Source | 1,896,000Source | 8,602,000Source | 12,595,000Source | 15,495,000Source | 3,740,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 2,200,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -180,000Source | -141,000Source | -53,000Source | -546,000Source | -75,000Source | -335,000Source | -700,000Source | -1,214,000Source | -660,000Source | -551,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 19,738,000Source | 103,648,000Source | 231,823,000Source | 231,986,000Source | 300,826,000Source | 415,873,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 6,994,000Source | 2,189,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | — | — | — | — | — | — | — | 400,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 95,000Source | 26,000Source |
| Restructuring Costs | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 416,000Source | — | 0Source | — | 0Source | 0Source | 87,371,000Source | 380,786,000Source | 22,230,000Source |
| Cost of RevenueUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 5,953,000Source | 25,441,000Source | 2,993,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 16,172,000Source | 17,828,000Source | 21,925,000Source | 15,640,000Source | 16,169,000Source | 15,684,000Source | 62,887,000Source | 114,331,000Source | 188,356,000Source | 127,128,000Source |
| Operating Income (Loss)USD | — | — | -36,027,000Source | -75,661,000Source | -45,693,000Source | -42,857,000Source | -43,779,000Source | -37,803,000Source | -153,291,000Source | -314,731,000Source | 38,802,000Source | -201,341,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -180,000Source | -141,000Source | -53,000Source | -546,000Source | -75,000Source | -335,000Source | -700,000Source | -1,214,000Source | -660,000Source | -551,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -34,386,000Source | -72,704,000Source | — | -41,443,000Source | — | -35,907,000Source | -144,689,000Source | -302,136,000Source | 54,297,000Source | -197,601,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 46,000Source | -393,000Source | 5,026,000Source | 774,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,386,000Source | -72,704,000Source | -43,423,000Source | -41,443,000Source | -41,284,000Source | -35,907,000Source | -144,735,000Source | -301,743,000Source | 49,271,000Source | -198,375,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.37Source | -1.07Source | -0.39Source | -0.46Source | -0.37Source | -0.42Source | -1.53Source | -4.43Source | 0.73Source | -3.39Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.37Source | -1.07Source | -0.39Source | -0.46Source | -0.37Source | -0.42Source | -1.53Source | -4.43Source | 0.7Source | -3.39Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 93,332,930Source | 68,091,446Source | 111,196,883Source | 89,138,568Source | 110,563,360Source | 85,697,108Source | 94,565,567Source | 68,142,158Source | 67,234,465Source | 58,495,587Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 93,332,930Source | 68,091,446Source | 111,196,883Source | 89,138,568Source | 110,563,360Source | 85,697,108Source | 94,565,567Source | 68,142,158Source | 69,991,340Source | 58,495,587Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 36,027,000Source | 76,077,000Source | 45,693,000Source | 42,857,000Source | 43,779,000Source | 37,803,000Source | 153,291,000Source | 402,102,000Source | 341,984,000Source | 223,571,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 46,000Source | -617,000Source | 5,250,000Source | 774,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -144,577,000Source | -301,757,000Source | 52,263,000Source | -198,704,000Source |
| Investment Income, InterestUSD | — | — | 1,821,000Source | 3,098,000Source | 2,323,000Source | 1,960,000Source | 2,570,000Source | 2,231,000Source | 9,302,000Source | 13,809,000Source | 16,155,000Source | 4,291,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,641,000Source | 2,957,000Source | 2,270,000Source | 1,414,000Source | 2,495,000Source | 1,896,000Source | 8,602,000Source | 12,595,000Source | 15,495,000Source | 3,740,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 2,200,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 19,855,000Source | 21,237,000Source | 23,768,000Source | 27,217,000Source | 27,610,000Source | 22,119,000Source | 90,404,000Source | 104,084,000Source | 128,187,000Source | 93,450,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | — | — | — | — | — | — | — | 400,000Source | — |
| Restructuring Costs | — | — | — | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-293956
Filing attachments
d184004dex991.htm · 8-K · 2026-08-18
EX-99.1 2 d184004dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia (PBH) Topline Data Conference Call August 18, 2026 Maggie, a mom and advocate living with post-bariatric hypoglycemia (PBH). Pancreatic islet cells Opening Remarks Lindsey Allen Vice President, Investor Relations & Communications at Amylyx DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking stateme…
Read attachment ↗d180533dex991.htm · 8-K · 2026-08-18
EX-99.1 2 d180533dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003) LUCIDITY met all secondary endpoints showing consistent, highly statistically significant, and clinically…
Read attachment ↗amlx-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 amlx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results • Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August or early September 2026 • Cash runway expected to fund operations into 2028 • Management to host conference call and webcast today at 8:00 a.m. Easte…
Read attachment ↗amlx-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 amlx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results • Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 • Cash runway expected to fund operations through potential avexitide commercialization and into 2028 • Management to host conference call and webcast today at 8:00 a.m. Eastern Time CAMBRIDGE, Mass. May 7, 2026 - Amylyx Pharmaceu…
Read attachment ↗d49067dex991.htm · 8-K · 2026-03-24
EX-99.1 2 d49067dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 MARCH 2026 We have an audacious mission to develop novel therapies for diseases with high unmet needs, with a focus on serious and fatal endocrine conditions and neurodegenerative diseases. Maggie, a mom and advocate living with post-bariatric hypoglycemia (PBH). Pancreatic islet cells DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meanin…
Read attachment ↗d82596dex43.htm · S-3ASR · 2026-03-03
Exhibit 4.3 AMYLYX PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS 1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 …
Read attachment ↗